AAD 2023: Novel TYK2 Inhibitor Shows Promise for Psoriasis
Significant improvements seen in psoriasis severity for doses ≥5 mg, with an acceptable safety profile
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.